UA108250C2 - Парентеральна фармацевтична композиція, її застосування та способи лікування або попередження віл-інфекції у людини - Google Patents
Парентеральна фармацевтична композиція, її застосування та способи лікування або попередження віл-інфекції у людиниInfo
- Publication number
- UA108250C2 UA108250C2 UAA201303057A UAA201303057A UA108250C2 UA 108250 C2 UA108250 C2 UA 108250C2 UA A201303057 A UAA201303057 A UA A201303057A UA A201303057 A UAA201303057 A UA A201303057A UA 108250 C2 UA108250 C2 UA 108250C2
- Authority
- UA
- Ukraine
- Prior art keywords
- prevention
- hiv
- treatment
- methods
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38354110P | 2010-09-16 | 2010-09-16 | |
PCT/US2011/051713 WO2012037320A2 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
UA108250C2 true UA108250C2 (uk) | 2015-04-10 |
Family
ID=45832235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201303057A UA108250C2 (uk) | 2010-09-16 | 2011-09-15 | Парентеральна фармацевтична композиція, її застосування та способи лікування або попередження віл-інфекції у людини |
Country Status (28)
Country | Link |
---|---|
US (3) | US20130171214A1 (ru) |
EP (1) | EP2616076B1 (ru) |
JP (1) | JP6231385B2 (ru) |
KR (1) | KR101938662B1 (ru) |
CN (1) | CN103547266B (ru) |
AU (1) | AU2011302030B2 (ru) |
BR (1) | BR112013005907B1 (ru) |
CA (1) | CA2810524C (ru) |
CL (1) | CL2013000715A1 (ru) |
CY (1) | CY1118279T1 (ru) |
DK (1) | DK2616076T3 (ru) |
EA (1) | EA024924B1 (ru) |
ES (1) | ES2594557T3 (ru) |
HR (1) | HRP20161280T1 (ru) |
HU (1) | HUE031336T2 (ru) |
IL (1) | IL225028A (ru) |
LT (1) | LT2616076T (ru) |
ME (1) | ME02520B (ru) |
MX (1) | MX346193B (ru) |
PL (1) | PL2616076T3 (ru) |
PT (1) | PT2616076T (ru) |
RS (1) | RS55222B1 (ru) |
SI (1) | SI2616076T1 (ru) |
SM (1) | SMT201600350B (ru) |
TW (1) | TWI577377B (ru) |
UA (1) | UA108250C2 (ru) |
WO (1) | WO2012037320A2 (ru) |
ZA (1) | ZA201301766B (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
WO2014093941A1 (en) | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Pharmaceutical compositions |
US9808428B2 (en) | 2014-01-14 | 2017-11-07 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
US20170165271A1 (en) * | 2014-02-24 | 2017-06-15 | The Board Of Regents Of The University Of Nebraska | Compositions and Methods for the Delivery of Therapeutics |
CN106999425A (zh) * | 2014-09-26 | 2017-08-01 | 葛兰素史克知识产权第二有限公司 | 长效药物组合物 |
WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
KR20170099911A (ko) * | 2014-12-20 | 2017-09-01 | 트로이카 파마슈티칼스 리미티드 | 파라세타몰 주사 제제 |
US11117904B2 (en) | 2016-06-23 | 2021-09-14 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
US11077050B2 (en) | 2017-03-24 | 2021-08-03 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
US20200138845A1 (en) * | 2017-07-18 | 2020-05-07 | Viiv Healthcare Company | Combination Drug Therapy |
WO2019140365A1 (en) | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
WO2020086555A1 (en) | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
CN109646440B (zh) * | 2019-01-11 | 2021-04-20 | 山东省农业科学院奶牛研究中心 | Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用 |
LT3938047T (lt) | 2019-03-22 | 2022-10-10 | Gilead Sciences, Inc. | Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje |
MX2022006940A (es) * | 2019-12-09 | 2022-07-11 | Viiv Healthcare Co | Composiciones farmaceuticas. |
JP7453399B2 (ja) | 2020-02-24 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv感染症を治療するための四環式化合物及びその使用 |
CA3184868A1 (en) * | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
US20230321089A1 (en) * | 2020-09-01 | 2023-10-12 | Viiv Healthcare Company | Combination of cabotegravir and levonorgestrel |
WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
KR20230134529A (ko) | 2021-01-19 | 2023-09-21 | 길리애드 사이언시즈, 인코포레이티드 | 치환된 피리도트리아진 화합물 및 이의 용도 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
CN115844838B (zh) * | 2022-12-01 | 2023-10-24 | 浙江萃泽医药科技有限公司 | 一种可注射的药物组合物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1215599A (fr) * | 1958-06-27 | 1960-04-19 | Rhone Poulenc Sa | Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
AU723537B2 (en) | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
JP5160005B2 (ja) * | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
EP1578434A2 (en) * | 2002-07-09 | 2005-09-28 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
JP2007501683A (ja) | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | γ線照射によるナノ粒子活性物質分散体の滅菌法 |
US20080214808A1 (en) | 2005-04-25 | 2008-09-04 | Thomas Frederik Ernestine Spittaels | Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester |
LT3284520T (lt) * | 2005-04-28 | 2019-09-25 | Viiv Healthcare Company | Policiklinis karbamoilpiridono darinys, turintis živ integrazę slopinantį poveikį |
US7601355B2 (en) * | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
UA96436C2 (ru) * | 2006-01-20 | 2011-11-10 | Тиботек Фармасьютикелз Лтд. | Долгосрочное лечение вич-инфекции |
US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
ES2437331T3 (es) * | 2007-07-12 | 2014-01-10 | Janssen R&D Ireland | Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo |
SI2234617T1 (sl) * | 2007-12-19 | 2021-07-30 | Janssen Pharmaceutica Nv | Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje |
TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
WO2009128918A1 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
KR101772610B1 (ko) * | 2008-07-25 | 2017-09-12 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
JP5572168B2 (ja) | 2008-12-11 | 2014-08-13 | ビーブ・ヘルスケア・カンパニー | カルバモイルピリドンhivインテグラーゼ阻害剤の製造方法および中間体 |
WO2010068253A1 (en) | 2008-12-11 | 2010-06-17 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
WO2011017395A1 (en) | 2009-08-04 | 2011-02-10 | Glaxosmithkline Llc | Chemical compounds |
US20110152303A1 (en) | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Chemical Compounds |
-
2011
- 2011-09-14 TW TW100133064A patent/TWI577377B/zh active
- 2011-09-15 RS RS20160826A patent/RS55222B1/sr unknown
- 2011-09-15 PL PL11825920T patent/PL2616076T3/pl unknown
- 2011-09-15 MX MX2013003037A patent/MX346193B/es active IP Right Grant
- 2011-09-15 AU AU2011302030A patent/AU2011302030B2/en active Active
- 2011-09-15 ES ES11825920.9T patent/ES2594557T3/es active Active
- 2011-09-15 JP JP2013529316A patent/JP6231385B2/ja active Active
- 2011-09-15 ME MEP-2016-192A patent/ME02520B/me unknown
- 2011-09-15 US US13/823,316 patent/US20130171214A1/en not_active Abandoned
- 2011-09-15 KR KR1020137009569A patent/KR101938662B1/ko active IP Right Grant
- 2011-09-15 SI SI201130966A patent/SI2616076T1/sl unknown
- 2011-09-15 LT LTEP11825920.9T patent/LT2616076T/lt unknown
- 2011-09-15 HU HUE11825920A patent/HUE031336T2/hu unknown
- 2011-09-15 BR BR112013005907-9A patent/BR112013005907B1/pt active IP Right Grant
- 2011-09-15 EA EA201390233A patent/EA024924B1/ru unknown
- 2011-09-15 DK DK11825920.9T patent/DK2616076T3/en active
- 2011-09-15 WO PCT/US2011/051713 patent/WO2012037320A2/en active Application Filing
- 2011-09-15 UA UAA201303057A patent/UA108250C2/ru unknown
- 2011-09-15 CN CN201180044588.5A patent/CN103547266B/zh active Active
- 2011-09-15 EP EP11825920.9A patent/EP2616076B1/en active Active
- 2011-09-15 PT PT118259209T patent/PT2616076T/pt unknown
- 2011-09-15 CA CA2810524A patent/CA2810524C/en active Active
-
2013
- 2013-03-03 IL IL225028A patent/IL225028A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01766A patent/ZA201301766B/en unknown
- 2013-03-15 CL CL2013000715A patent/CL2013000715A1/es unknown
-
2016
- 2016-10-04 CY CY20161100985T patent/CY1118279T1/el unknown
- 2016-10-04 SM SM201600350T patent/SMT201600350B/it unknown
- 2016-10-05 HR HRP20161280TT patent/HRP20161280T1/hr unknown
- 2016-10-13 US US15/292,394 patent/US11224597B2/en active Active
-
2021
- 2021-12-10 US US17/547,682 patent/US20220096469A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA108250C2 (uk) | Парентеральна фармацевтична композиція, її застосування та способи лікування або попередження віл-інфекції у людини | |
AU2018256591A1 (en) | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | |
PH12016500389B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MY170941A (en) | Pyrimidine derivatives for the treatment of viral infections | |
PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
NZ598766A (en) | Macrocyclic integrase inhibitors | |
MX2015007563A (es) | Composiciones farmaceuticas. | |
MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
MY192716A (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors | |
NZ627827A (en) | Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | |
NZ585226A (en) | Inhibitors of human immunodeficiency virus replication | |
CL2011002878A1 (es) | Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih. | |
MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
WO2011160024A3 (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
EP2555798A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS | |
MX2022001261A (es) | Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. | |
MA40805A (fr) | Compositions pharmaceutiques à action prolongée contre l'hépatite c | |
CL2015000659A1 (es) | Compuestos derivados de macrólidos; proceso de preparación; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de infecciones bacterianas. | |
UY31888A (es) | Compuestos de 1,1-dióxido de [1,2,4,]tiadiazina |